GENEREX BIOTECHNOLOGY CORPORATION (OTCMKTS:GNBT) Files An 8-K Other EventsItem 8.01. Other Events
On January 2, 2018, the Company issued a press release confirming payment by Shenzhen BioScien Pharmaceuticals Co., Ltd. (“Shenzen’) of the $700,000 USD up-front license fee (net of applicable Chinese withholding taxes) payable by Shenzhen under the License and Research Agreement entered into with the Company’s wholly-owned subsidiary Antigen Express, Inc.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.
GENEREX BIOTECHNOLOGY CORP ExhibitEX-99.1 2 ex99.htm EXHIBIT 99.1 EXHIBIT 99.1 Generex Confirms Receipt of $700,…To view the full exhibit click here
About GENEREX BIOTECHNOLOGY CORPORATION (OTCMKTS:GNBT)
Generex Biotechnology Corporation is a development-stage company. The Company is engaged primarily in the research and development of drug delivery systems and technologies. The Company is focused on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its buccal delivery technology is a platform technology that has application to various large molecule drugs and provides a non-invasive way to administer such drugs. The Company focuses its development efforts on Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its hand-held aerosol spray applicator known as RapidMist. Its subsidiary, Antigen Express, Inc., focuses on developing vaccine formulations that work by stimulating the immune system to either attack offending agents, such as cancer cells, bacteria and viruses, or to stop attacking benign elements, such as self proteins and allergens.